Gainers

• Day One Biopharmaceutical (NASDAQ:DAWN) stock rose 65.7% to $21.18 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion.
• Edesa Biotech (NASDAQ:EDSA) stock increased by 56.23% to $5.64. The company's market cap stands at $30.1 million.
• Firefly Neuroscience (NASDAQ:AIFF) shares increased by 36.97% to $1.95. The market value of their outstanding shares is at $20.1 million.
• AN2 Therapeutics (NASDAQ:ANTX) stock increased by 33.91% to $2.29. The company's market cap stands at $46.8 million.
• Pulmonx (NASDAQ:LUNG) stock increased by 32.29% to $2.13. The company's market cap stands at $66.4 million. As per the news, the Q4 earnings report came out 2 days ago.
• Q/C Technologies (NASDAQ:QCLS) stock increased by 31.6% to $4.58. The market value of their outstanding shares is at $27.3 million.

Losers

• Calidi Biotherapeutics (AMEX:CLDI) stock decreased by 50.7% to $0.38 during Friday's regular session. The market value of their outstanding shares is at $5.5 million.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock declined by 40.31% to $0.1.
• Owlet (NYSE:OWLT) stock fell 36.01% to $7.52. The company's market cap stands at $324.0 million. The company's, Q4 earnings came out yesterday.
• Medicus Pharma (NASDAQ:MDCX) stock fell 35.5% to $0.44. The market value of their outstanding shares is at $16.7 million.
• Lunai Bioworks (NASDAQ:LNAI) shares declined by 28.91% to $0.26. The company's market cap stands at $8.7 million.
• OptimizeRx (NASDAQ:OPRX) shares fell 17.93% to $6.18. The company's market cap stands at $139.2 million. The company's, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.